Antitumor activity of doxorubicin in combination with docetaxel against human breast cancer xenografts

Tomohisa Egawa, Tetsuro Kubota, Akihiko Suto, Yoshihide Otani, Toshiharu Furukawa, Yoshiro Saikawa, Masahiko Watanabe, Koichiro Kumai, Masaki Kitajima

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)


In this study we assessed the inyivo antitumor activity of combined docetaxel (DOCE) and doxorubicin (DXR) treatment using 2 human breast carcinoma cell xenografts (R-27 and MX-1) in the nude mouse model. The transplanted tumors were allowed to reach exponential growth, whereupon 10 or 40 mg DOCE per kg alone (ip), 8 mg DXR per kg alone (iv), or 10 mg/kg DOCE (ip) and 8 mg/kg of DXR (iv), in the sequence of DOCE followed by DXR, were administered. The in vivo antitumor activity of combined DOCE and DXR was synergistic against R-27 and additive against MX-1. P-gfycoprotein (P-gp) was detected immunohistochemically, and was highly expressed in R-27, but not in MX-1. In conclusion, DOCE may increase the antitumor activity of DXR against P-gp-positive breast cancer xenografts, such that the DOCE and DXR combination may be a useful treatment in clinical breast cancer.

Original languageEnglish
Pages (from-to)23-28
Number of pages6
JournalIn Vivo
Issue number1
Publication statusPublished - 2003


  • Breast cancer
  • Combination therapy
  • Docetaxel
  • Doxorubicin
  • In vivo
  • P-glycoprotein
  • Synergism

ASJC Scopus subject areas

  • General Biochemistry,Genetics and Molecular Biology
  • Pharmacology


Dive into the research topics of 'Antitumor activity of doxorubicin in combination with docetaxel against human breast cancer xenografts'. Together they form a unique fingerprint.

Cite this